Compare Amgen, Inc. (AMGN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Tesla, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Tesla, Inc. trades at $404.8 (market cap $1.53T). The key difference: Tesla, Inc. is far larger — about 7.8× Amgen, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | TSLA | |
|---|---|---|
Market Cap | $196.12B | $1.53T |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $489.88 |
52-Week Low | $271.18 | $302.63 |
Enterprise Value | $241.41B | $1.50T |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Tesla (TSLA) trades at $407.74, up 0.29% today, with a neutral technical signal and key support at $396. The stock shows elevated valuation multiples (P/E 374.09, P/S 14.72) amid declining profitability, with net income margin falling to 3.95% in 2025. Recent Q1 2026 earnings beat expectations, but revenue growth has stalled. News highlights focus on Tesla's pivot to AI, robotics, and regulatory approval for self-driving software in Europe (Reuters, 2026-04-10).
Outlook remains bifurcated: long-term optimism around autonomy and energy growth contrasts with near-term EV demand pressures and high valuation risks. Analyst consensus is mixed with a $436.41 price target, but competitive and execution risks persist. Cash flow stability improved with net positive $579M in 2025, though investing outflows remain high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
